Role of the Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention

Environmental Health Perspectives

Volumn 107, Issue SUPPL. 1, 1999, Pages 49-57

  Chaudhary, Khurram S ^b   Abel, Paul D ^a   Lalani, El Nasir ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b Imperial College School of Medicine ^*

Author keywords

Apoptosis; Bcl 2 family; Prostate cancer; Therapeutics

Indexed keywords

ANDROGEN; CYTOTOXIC AGENT; PROTEIN BCL 2;

APOPTOSIS; CANCER GROWTH; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CHEMOTHERAPY; HUMAN; LYMPH NODE; MALE; MULTIGENE FAMILY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW;

EID: 0032963369     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.99107s149     Document Type: Review

References (143)

1. Wingo PA, Landis S, Ries LA. An adjustment to the 1997 estimate for new prostate cancer cases. Cancer 80:1810-1813 (1997).
2. Horm J, Sondik E. Person-years of life lost due to cancer in the United States 1970-1984. Am J Public Health 79:1490-1493 (1989).
3. Devesa SS, Blot WJ, Stone BJ, Miller BA, Tarone RE, Fraumeni JF Jr. Recent cancer trends in the United States. J Natl Cancer Inst 87:175-182 (1995).
4. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 89:3367-3371 (1992).
5. Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CC, Willett WC. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 85:1571-1579 (1993).
6. Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, Howe GR, Burch JD, Hankin J, Dreon DM, West DW, et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 87:652-661 (1995).
7. Fair WR, Fleshner NE, Heston W. Cancer of the prostate: a nutritional disease? Urology 50:840-848 (1997).
8. The effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group. N Engl J Med 330:1029-1035 (1994).
9. Epstein JI. Prostatic intraepithelial neoplasia. Adv Anat Pathol 1:123-134 (1994).
10. Bostwick DG. Is behaviour of prostate cancer understood? In: Questions and Uncertainties About Prostate Cancer (Peeling WB, ed). Oxford:Blackwell Science, 1996:30-49.
11. Gleason D. Classification of prostatic carcinomas. Cancer Chemother Rep 50:125-128 (1966).
12. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111:58-64 (1974).
13. Saitoh H, Hida M, Shimbo T. Metastatic patterns of prostatic cancer: correlation between sites and number of organs involved. Cancer 54:3078-3084 (1994).
14. Isaacs JT. Molecular markers for prostate cancer metastasis. Am J Pathol 150:1511-1521 (1997).
15. Lalani E, Stubbs A, Stamp GWH. Molecular genetic changes in prostate cancer. In: Progress in Pathology, Vol 4. New York:Churchill Livingstone, 1998:113-135.
16. Lalani EN, Stubbs A, Stamp GW. Prostate cancer: the interface between pathology and basic scientific research. Semin Cancer Biol 8:53-59 (1997).
17. Lalani E, Laniado M, Abel P. Molecular and cellular biology of prostate cancer. Cancer Metastasis Rev 16:29-66 (1997).
18. Schroder FH. Detection of prostate cancer [editorial]. Br Med J 310:140-141 (1995).
19. Boyle P, Maisonneuve P, Napalkov P. Incidence of prostate cancer will double by the year 2030: the argument for. Eur Urol 29(Suppl 2):3-9 (1996).
20. Whitmore WF Jr. Natural history of low-stage prostatic cancer and the impact of early detection. Urol Clin North Am 17:689-697 (1990).
21. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 152:1831-1836 (1994).
22. Hancock SL, Cox RS, Bagshaw MA. Prostate specific antigen after radiotherapy for prostate cancer: a reevaluation of long-term biochemical control and the kinetics of recurrence in patients treated at Stanford University. J Urol 154:1412-1417 (1995).
23. Westin P, Stattin P, Damber JE, Bergh A. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol 146:1368-1375 (1995).
24. Hakimi J, Rondinelli R, Schoenberg M, Barrack E. Androgen receptor gene structure and function in prostate cancer. World J Urol 14:329-337 (1996).
25. Brinkmann AO, Jenster G. Ris Stalpers C, van der Korput JA, Bruggenwirth HT, Boehmer AL, Trapman J. Androgen receptor mutations. J Steroid Biochem Mol Biol 53:443-448 (1995).
26. Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J. Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 46:759-765 (1993).
27. Trapman J, Brinkmann AO. Mutations in the androgen receptor. Ann NY Acad Sci 684:85-93 (1993).
28. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9:401-406 (1995).
29. Koivisto P, Visakorpi T, Kallioniemi OP. Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer. Scand J Clin Lab Invest Suppl 226:57-63 (1996).
30. Ruizeveld de Winter JA, Janssen PJ, Sleddens HM, Verleun Mooijman MC, Trapman J, Brinkmann AO, Santerse AB, Schroder FH, van der Kwast TH. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 144:735-746 (1994).
31. Elo JP, Kvist L, Leinonen K, Isomaa V, Henttu P, Lukkarinen O, Vihko P. Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol. J Clin Endocrinol Metab 80:3494-3500 (1995).
32. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143:390-400 (1993).
33. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55:4438-4445 (1995).
34. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944 (1992).
35. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71:1098-1109 (1993).
36. Barr PJ, Tomei LD. Apoptosis and its role in human disease. Biotechnology NY 12:467-493 (1994).
37. Strasser A, Huang DC, Vaux DL. The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy. Biochim Biophys Acta 1333:F151-F178 (1997).
38. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 267:1456-1462 (1995).
39. Kerr J, Wyllie A, Currie A. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer 26:239-257 (1972).
40. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 73:2013-2026 (1994). [Published erratum appears in Cancer 73:3108 (1994).]
41. Wyllie A, Kerr J, Currie A. Cell death: the significance of apoptosis. Int Rev Cytol 68:251-306 (1980).
42. Wyllie A, Morris R, Smith A, Dunlop D. Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol 142:66-72 (1984).
43. Hengartner MO, Ellis RE, Horvitz HR. Caenorhabditis elegans gene ced-9 protects cells from programmed cell death. Nature 356:494-499 (1992).
44. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90:405-413 (1997).
45. Vaux DL, Cory S, Adams JM. Bcl-2 gene promates haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440-442 (1988).
46. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334-336 (1990).
47. Reed JC, Cuddy M, Haldar S, Croce C, Nowell P, Makover D, Bradley K. BCL2-mediated tumorigenicity of a human T-lymphoid cell line: synergy with MYC and inhibition by BCL2 anti-sense. Proc Natl Acad Sci USA 87:3660-3664 (1990).
48. Reed JC, Stein C, Subasinghe C, Haldar S, Croce CM, Yum S, Cohen J. Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res 50:6565-6570 (1990).
49. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 124:1-6 (1994).
50. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 228:1440-1443 (1985).
51. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226:1097-1099 (1984).
52. Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 47:19-28 (1986).
53. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609-619 (1993).
54. Zha H. Aime Sempe C, Sato T, Reed JC. Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2. J Biol Chem 271:7440-7444 (1996).
55. Han J, Sabbatini P, Perez D, Rao L, Modha D, White E. The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein. Genes Dev 10:461-477 (1996).
56. Yin XM, Oltval ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 369:321-323 (1994).
57. Hanada M, Aime Sempe C, Sato T, Reed JC. Structure-function analysis of Bcl-2 protein. Identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax. J Biol Chem 270:11962-11969 (1995).
58. Reed J. Bcl-2 family proteins: strategies for overcoming chemoresistance in cancer. Adv Pharmacol 41:501-532 (1997).
59. Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 53:4701-4714 (1993).
60. Lithgow T, van Driel R, Bertram JF, Strasser A. The protein product of the oncogene bcl-2 is a component of the nuclear envelope, the endoplasmic reticulum, and the outer mitochondrial membrane. Cell Growth Differ 5:411-417 (1994).
61. Kane DJ, Sarafian TA, Anton R, Hahn H, Gralla EB, Valentine JS, Ord T, Bredesen DE. Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science 262:1274-1277 (1993).
62. Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75:241-251 (1993).
63. L. Nature 374:811-813 (1995).
64. Jacobson MD, Raff MC. Programmed cell death and Bcl-2 protection in very low oxygen. Natur 374:814-816 (1995).
65. 2+ pool depletion. Oncogene 12:2051-2055 (1996).
66. Baffy G, Miyashita T, Williamson JR, Reed JC. Apoptosis induced by withdrawal of interleukin-3 (IL-3) from an IL-3-dependent hematopoietic cell line is associated with repartitioning of intracellular calcium and is blocked by enforced Bcl-2 oncoprotein production. J Biol Chem 268:6511-6519 (1993).
67. 2+ fluxes. Proc Natl Acad Sci USA 91:6569-6573 (1994).
68. 2+. Oncogene 12:2259-2266 (1996).
69. Murphy AN, Bredesen DE, Cortopassi G, Wang E, Fiskum G. Bcl-2 potentiates the maximal calcium uptake capacity of neural cell mitochondria. Proc Natl Acad Sci USA 93:9893-9898 (1996).
70. Ryan JJ, Prochownik E, Gottlieb CA, Apel IJ, Merino R, Nunez G, Clarke MF. c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. Proc Natl Acad Sci USA 91:5878-5882 (1994).
71. Meikrantz W, Gisselbrecht S, Tam SW, Schlegel R. Activation of cyclin A-dependent protein kinases during apoptosis. Proc Natl Acad Sci USA 91:3754-3758 (1994).
72. Hengartner MO, Horvitz HR. Programmed cell death in Caenorhabditis elegans. Curr Opin Genet Dev 4:581-586 (1994).
73. Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, Wong WW, Yuan J. Human ICE/CED-3 protease nomenclature [letter]. Cell 87:171 (1996).
74. Boulakia CA, Chen G, Ng FW, Teodoro JG, Branton PE, Nicholson DW, Poirier GG, Shore GC. Bcl-2 and adenovirus E1B 19 kDA protein prevent E1A-induced processing of CPP32 and cleavage of poly(ADP-ribose) polymerase. Oncogens 12:529-535 (1996).
75. Monney L, Otter I, Olivier R, Ravn U, Mirzasaleh H, Fellay I, Poirier GG, Borner C. Bcl-2 overexpression blocks activation of the death protease CPP32/Yama/apopain. Biochem Biophys Res Commun 221:340-345 (1996).
76. Srinivasan A, Foster LM, Testa MP, Ord T, Keane RW, Bredesen DE, Kayalar C. Bcl-2 expression in neural cells blocks activation of ICE/CED-3 family proteases during apoptosis. J Neurosci 16:5654-5660 (1996).
77. L inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Cancer Res 56:4743-4748 (1996).
78. Smyth MJ, Perry DK, Zhang J, Poirier GG, Hannun YA, Obeid LM. a downstream target for ceramide-induced apoptosis and for the inhibitory action of Bcl-2. Biochem J 316:25-28 (1996).
79. Messmer UK, Reimer DM, Reed JC, Brune B. Nitric oxide induced poly(ADP-ribose) polymerase cleavage in RAW 264.7 macrophage apoptosis is blocked by Bcl-2. FEBS Lett 384:162-166 (1996).
80. Zamzami N, Susin SA, Marchetti P, Hirsch T, Gomez Monterrey I, Castedo M, Kroemer G. Mitochondrial control of nuclear apoptosis. J Exp Med 183:1533-1544 (1996).
81. Susin SA, Zamzami N, Castedo M, Hirsch T, Marchetti P, Macho A, Daugas E, Geuskens M, Kroemer G. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J Exp Med 184:1331-1341 (1996).
82. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86:147-157 (1996).
83. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275:1129-1132 (1997).
84. Antonsson B, Conti F, Ciavatta A, Montessuit S, Lewis S, Martinou I, Bernasconi L, Bernard A, Mermod JJ, Mazzei G, et al. Inhibition of Bax channel-forming activity by Bcl-2. Science 277:370-372 (1997).
85. Schlesinger PH, Gross A, Yin XM, Yamamoto K, Saito M, Waksman G, Korsmeyer SJ. Comparison of the ion channel characteristics of proapoptotic BAX and antiapoptotic BCL-2. Proc Natl Acad Sci USA 94:11357-11362 (1997).
86. Schendel SL, Xie Z, Montal MO, Matsuyama S, Montai M, Reed JC. Channel formation by anti-apoptotic protein Bcl-2. Proc Natl Acad Sci USA 94:5113-5118 (1997).
87. (L) forms an ion channel in synthetic lipid membranes. Nature 385:353-357 (1997).
88. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81:151-157 (1993).
89. Miyashita T, Reed JC. bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 52:5407-5411 (1992).
90. Walton MI, Whysong D, O'Connor PM, Hockenbery D, Korsmeyer SJ, Kohn KW. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res 53:1853-1861 (1993).
91. Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizawa A, Pommier Y, Cossman J. bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res; 53: 4251-4256 (1993). [Published erratum appears in Cancer Res 54:3074 (1994).]
92. Fisher TC, Milner AE, Gregory CD, Jackman AL, Aherne GW, Hartley JA, Dive C, Hickman JA. bcl-2 modulation of apoptosis induced by anti-cancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res 53:3321-3326 (1993).
93. Tang C, Willingham MC, Reed JC, Miyashita T, Ray S, Ponnathpur V, Huang Y, Mahoney ME, Bullock G, Bhalla K. High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia 8:1960-1699 (1994).
94. L can confer a multidrug resistance phenotype. Blood 86:1903-1910 (1995).
95. McConkey DJ, Greene G, Pettaway CA. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res 56:5594-5599 (1996).
96. Vaux DL, Strasser A. The molecular biology of apoptosis. Proc Natl Acad Sci USA 93: 2239-2244 (1996).
97. Campos L, Sabido O, Rouault JP, Guyotat D. Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood 84:595-600 (1994).
98. Berchem GJ, Bosseler M, Sugars LY, Voeller HJ, Zeitlin S, Gelmann EP. Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res 55:735-738 (1995).
99. Kitada S, Takayama S, De Riel K, Tanaka S, Reed JC. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev 4:71-79 (1994).
100. (L) gene expression. FEBS Lett 407:97-100 (1997).
101. Bargou RC, Bommert K, Weinmann P, Daniel PT, Wagener C, Mapara MY, Dorken B. Induction of Bax-alpha precedes apoptosis in a human B lymphoma cell line: potential role of the bcl-2 gene family in surface IgM-mediated apoptosis. Eur J Immunol 25:770-775 (1995).
102. Bargou RC, Wagener C, Bommert K, Mapara MY, Daniel PT, Arnold W, Dietel M, Guski H, Feller A, Royer HD, et al. Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J Clin Invest 97:2651-2659 (1996).
103. S sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res 55:2507-2510 (1995).
104. Berges R. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1:473-480 (1995).
105. Isaacs JT, Lundmo PI, Berges R, Martikainen P, Kyprianou N, English HF. Androgen regulation of programmed death of normal and malignant prostatic cells. J Androl 13:457-464 (1992).
106. Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 50:3748-3753 (1990).
107. Denmeade SR, Isaacs JT. Activation of programmed (apoptotic) cell death for the treatment of prostate cancer. Adv Pharmacol 35:281-305 (1996).
108. Lin XS, Denmeade SR, Cisek L, Isaacs JT. Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin. Prostate 33:201-207 (1997).
109. 2(+)-ATPase inhibitor, thapsigargin. Agents Actions 29:8-15 (1990).
110. Gee JM, Robertson JF, Ellis IQ, Willsher P, McClelland RA, Hoyle HB, Kyme SR, Finlay P, Blamey RW, Nicholson RI. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 59:619-628 (1994).
111. Lauwers GY, Scott GV, Karpeh MS. Immunohistochemical evaluation of bcl-2 protein expression in gastric adenocarcinomas. Cancer 75:2209-2213 (1995).
112. Bhargava V, Kell DL, van de Rijn M, Warnke RA. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 145:535-540 (1994).
113. Pollina L, Pacini F, Fontanini G, Vignati S, Bevilacqua G, Basolo F. bcl-2, p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas. Br J Cancer 73:139-143 (1996).
114. Bubendorf L, Sauter G, Moch H, Jordan P, Blochlinger A, Gasser TC, Mihatsch MJ. Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am J Pathol 148:1557-1565 (1996).
115. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 148:1567-1576 (1996).
116. Apakama I, Robinson MC, Walter NM, Charlton RG, Royds JA, Fuller CE, Neal DE, Hamdy FC. bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer 74:1258-1262 (1996).
117. Tu H, Jacobs SC, Borkowski A, Kyprianou N. Incidence of apoptosis and cell proliferation in prostate cancer: relationship with TGF-beta1 and bcl-2 expression. Int J Cancer 69:357-363 (1996).
118. Tsuji M, Murakami Y, Kanayama H, Sano T. Kagawa S. Immunohistochemical analysis of Ki-67 antigen and Bcl-2 protein expression in prostate cancer: effect of neoadjuvant hormonal therapy. Br J Urol 81:116-121 (1998).
119. Byrne RL, Horne CH, Robinson MC, Autzen P, Apakama I, Bishop RI, Neal DE, Hamdy FC. The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. Br J Urol 79:190-195 (1997).
120. Segal NH, Cohen RJ, Haffejee Z, Savage N. BCL-2 proto-oncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell. Arch Pathol Lab Med 118:616-618 (1994).
121. Ben Ezra JM, Kornstein MJ, Grimes MM, Krystal G. Small cell carcinomas of the lung express the Bcl-2 protein. Am J Pathol 145:1036-1040 (1994).
122. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, Basolo F, Bevilacqua G. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 71:1003-1007 (1995).
123. Lu QL, Elia G, Lucas S, Thomas JA. Bcl-2 protooncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma. Int J Cancer 53:29-35 (1993).
124. Lu QL, Abel P, Foster CS, Lalani EN. bcl-2: role in epithelial differentiation and oncogenesis. Hum Pathol 27:102-110 (1996).
125. Bronner MP, Culin C, Reed JC, Furth EE. The bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model. Am J Pathol 146:20-26 (1995).
126. Shiina H, Igawa M, Urakami S, Honda S, Shirakawa H, Ishibe T. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder. J Clin Pathol 49:395-399 (1996).
127. Chaudhary KS, Lu QL, Abel PD, Khandan Nia N, Shoma AM, el Baz M, Stamp GW, Lalani EN. Expression of bcl-2 and p53 oncoproteins in schistosomiasis-associated transitional and squamous cell carcinoma of urinary bladder. Br J Urol 79:78-84 (1997).
128. Chaudhary KS, Stamp GWH, Abel PD, Lalani EN. Bcl-2 transfection into DU145 adenocarcinoma cells alters cell cycle regulatory molecules (p53, PCNA and Bax) and confers chemo-resistance against adriamycin and thapsigargin. Eur Urol 34:261 (1998).
129. Dorai T, Goluboff ET, Olsson CA, Buttyan R. Development of a hammerhead ribozyme against BCL-2. II: Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents. Anticancer Res 17:3307-3312 (1997).
130. Dorai T, Olsson CA, Katz AE, Buttyan R. Development of a hammerhead ribozyme against bcl-2. I: Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer. Prostate 32:246-258 (1997).
131. Kyprianou N, King ED, Bradbury D, Rhee JG. bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int J Cancer 70:341-348 (1997).
132. Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56:1253-1255 (1996).
133. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 57:229-233 (1997).
134. L overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human acute myeloid leukemia HL-60 cells. Cancer Res 57:1109-1115 (1997).
135. Boise LH, Gonzalez Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74:597-608 (1993).
136. Zhou P, Qian L, Kozopas KM, Craig RW. Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood 89:630-643 (1997).
137. Gibson L, Holmgreen SP, Huang DC, Bernard O, Copeland NG, Jenkins NA, Sutherland GR, Baker E, Adams JM, Cory S. bcl-w, a novel member of the bcl-2 family, promotes cell survival. Oncogene 13:665-675 (1996).
138. Lin EY, Orlofsky A, Wang HG, Reed JC, Prystowsky MB. A1, a Bcl-2 family member, prolongs cell survival and permits myeloid differentiation. Blood 87:983-992 (1996).
139. Chittenden T, Harrington EA, O'Connor R, Flemington C, Lutz RJ, Evan GI, Guild BC. Induction of apoptosis by the Bcl-2 homologue Bak. Nature 374:733-736 (1995).
140. L and Bcl-2, displaces Bax and promotes cell death. Cell 80:286-291 (1995).
141. Boyd JM, Gallo GJ, Elangovan B, Houghton AB, Malstrom S, Avery BJ, Ebb RG, Subramanian T, Chittenden T, Lutz RJ, et al. Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. Oncogene 11:1921-1928 (1995).
142. Wang K, Yin XM, Chao DT, Milliman CL, Korsmeyer SJ. BID: a novel BH3 domain-only death agonist. Genes Dev 10:2859-2869 (1996).
143. (L). EMBO J 16:1686-1694 (1997).